C2538

Carboplatin

Name: Carboplatin
Brand: SIGMA

DNA cross-linking agent, powder

Synonym(s):

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

Select a Size

All Photos(3)

About This Item

Linear Formula:

[C₄H₆(CO₂)₂]Pt(NH₃)₂

CAS Number:

41575-94-4

Molecular Weight:

371.25

NACRES:

NA.77

PubChem Substance ID:

24278303

UNSPSC Code:

12352200

EC Number:

255-446-0

MDL number:

MFCD00070464

Product Name

Carboplatin,

InChI key

OLESAACUTLOWQZ-UHFFFAOYSA-L

InChI

1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2

SMILES string

N.N.O=C1O[Pt]OC(=O)C12CCC2

form

powder

antibiotic activity spectrum

neoplastics

originator

Bristol-Myers Squibb

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

Application

Carboplatin has been used:

in chemotherapy-induced thrombocytopenia mouse model and treatment
to induce cell death in a large subset of colorectal cancer cells
in the evaluation of cell proliferation and chemosensitivity
as a positive control for suppressed cell growth

Biochem/physiol Actions

Carboplatin is a platinum-based antineoplastic drug that damages DNA by forming intrastrand cross-links with neighboring guanine residues. Tumors acquire resistance to these drugs through the loss of DNA-mismatch repair (MMR) activity and the resultant decrease in the induction of programmed cell death.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Carboplatin is used to treat testicular, ovarian and breast cancer.

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H302 + H312 + H332,H317,H334,H340,H360

pcodes

P202 - P261 - P280 - P301 + P312 - P302 + P352 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Sens. 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Osteoblasts support megakaryopoiesis through production of interleukin 9

Xiao M, et al.

Blood, blood-b2016 (2017)

Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials.

Furqan Shaikh et al.

Pediatric blood & cancer, 60(4), 587-592 (2012-09-15)

While cisplatin is considered superior to carboplatin for the treatment of malignant germ cell tumors (MGCTs) in adults, pediatric oncology collaborative groups still remain concerned about the late effects of cisplatin in children. We performed a literature search to identify

Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.

Joel Shapiro et al.

Annals of surgery, 258(5), 678-688 (2013-10-08)

To gain insight into the exact location of residual esophageal cancer in the esophageal wall and regional lymph nodes after neoadjuvant chemoradiotherapy (nCRT) and to determine the pattern of regression. Data from the recently published chemoradiotherapy for oesophageal cancer followed

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Michael D Nyquist et al.

Cell reports, 31(8), 107669-107669 (2020-05-28)

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant

Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?

Nikola A Bowden

Cancer letters, 346(2), 163-171 (2014-01-28)

Platinum based therapy is one of the most effectively used chemotherapeutic treatments for cancer. The mechanism of action of platinum compounds is to damage DNA and drive cells into apoptosis. The most commonly used platinum containing agents are cis-diammine-dichloroplatinum (II)]

View All Related Papers